Structure (Divalproex Sodium De Figure 1)
Divalproex Sodium Tablet, Delayed Release
Product Images NDC 69452-433
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 69452-433). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bionpharma Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure1 (Divalproex Sodium De Figure 2)
Figure2 (Divalproex Sodium De Figure 3)
Figure3 (Divalproex Sodium De Figure 4)
Figure4 (Divalproex Sodium De Figure 5)
Label1 (Divalproex Sodium De Figure 6)
This is a description of Divalproex Sodium Delayed-Release Tablets, USP, used for valproic acid activity. Each tablet contains Divalproex sodium USP equivalent to valproic acid 125 mg. The medication guide should be dispensed to each patient. The tablets should be stored in a tight, light-resistant container at 20° to 25°C. The product should not be accepted if the seal over the bottle opening is broken or missing. Distributed by Bionpharma Inc. It is made in India.*
Label2 (Divalproex Sodium De Figure 7)
This text is a product description for tablets containing Divalproex sodium, indicated for certain conditions. It provides information on dosing, storage instructions, and a reminder to keep the medication out of reach of children. The tablets are enteric-coated and delayed-release. The text indicates that they must be dispensed in a tight, light-resistant container and stored at a specified temperature range.*
Label3 (Divalproex Sodium De Figure 8)
This is a description of Divalproex Sodium Delayed-Release Tablets, USP with a strength of 500 mg. Each tablet contains Divalproex sodium USP equivalent to valproic acid. It is dispensed in a USP tight, light-resistant container and should be stored at 20° to 25°C (68° to 77°F). The packaging includes information on how to handle the medication properly and warns about keeping it out of reach of children. This medication is distributed by Bionpharma Inc., and the manufacturing location is in India. For full prescribing information, refer to the enclosed documentation.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
